Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Week In Review: Bio-Thera Raises $241 Million In Shanghai STAR IPO For Antibody Portfolio
Article By:
ChinaBio® Today
Saturday, February 15, 2020 4:19 PM EDT
Bio-Thera Solutions of Guangzhou priced its IPO on Shanghai’s STAR Board to raise $241 million at a valuation of almost $2 billion. The offering, which placed 60 million shares at RMB32.76 each, was reported to be 3,225 times oversubscribed.
Week In Review: AkesoBio Files For $300 Million Hong Kong IPO
Article By:
ChinaBio® Today
Saturday, February 8, 2020 4:16 PM EDT
AkesoBio, a Zhongshan novel drug discovery and development biopharma, filed for a $300 million Hong Kong IPO to develop its portfolio of novel mono- and bi-specific antibodies.
Week In Review: South Korea's Celltrion Plans $513 Million Biologics Facility In Wuhan
Article By:
ChinaBio® Today
Saturday, January 25, 2020 4:50 PM EDT
Celltrion, a South Korea biopharma, plans to build a $513 million China biologics manufacturing facility in Wuhan. The company said the plant's 120,000 liter capacity will make it the largest facility in China.
Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
Article By:
ChinaBio® Today
Saturday, January 11, 2020 4:11 PM EDT
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.